Lyra Therapeutics, Inc. (LYRA)
OTCMKTS
· Delayed Price · Currency is USD
0.710
-0.040 (-5.33%)
At close: Apr 28, 2026
Lyra Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Revenue | 0.4 | 1.53 | 1.56 | 1.36 | 0.29 | Upgrade
|
| Revenue Growth (YoY) | -74.06% | -1.54% | 14.31% | 378.25% | - | Upgrade
|
| Cost of Revenue | 1.01 | 1.36 | 48.03 | 38.8 | 29.69 | Upgrade
|
| Gross Profit | -0.61 | 0.17 | -46.47 | -37.43 | -29.41 | Upgrade
|
| Selling, General & Admin | 11.54 | 18.5 | 19.06 | 17.56 | 14.21 | Upgrade
|
| Research & Development | 17.41 | 42.41 | - | - | - | Upgrade
|
| Operating Expenses | 28.95 | 60.91 | 19.06 | 17.56 | 14.21 | Upgrade
|
| Operating Income | -29.55 | -60.73 | -65.53 | -54.99 | -43.62 | Upgrade
|
| Interest & Investment Income | 1.13 | 2.95 | 4.5 | 1.04 | 0.1 | Upgrade
|
| EBT Excluding Unusual Items | -28.42 | -57.78 | -61.03 | -53.95 | -43.51 | Upgrade
|
| Merger & Restructuring Charges | -1.47 | -10.9 | - | - | - | Upgrade
|
| Asset Writedown | - | -24.72 | -1.59 | -1.32 | - | Upgrade
|
| Other Unusual Items | 0.98 | - | - | - | - | Upgrade
|
| Pretax Income | -28.91 | -93.4 | -62.62 | -55.27 | -43.51 | Upgrade
|
| Income Tax Expense | 0.01 | 0.04 | 0.06 | 0.01 | - | Upgrade
|
| Net Income | -28.92 | -93.44 | -62.68 | -55.28 | -43.51 | Upgrade
|
| Net Income to Common | -28.92 | -93.44 | -62.68 | -55.28 | -43.51 | Upgrade
|
| Shares Outstanding (Basic) | 2 | 1 | 1 | 1 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 2 | 1 | 1 | 1 | 0 | Upgrade
|
| Shares Change (YoY) | 19.29% | 30.74% | 64.72% | 132.83% | 51.17% | Upgrade
|
| EPS (Basic) | -18.62 | -71.75 | -62.93 | -91.41 | -167.54 | Upgrade
|
| EPS (Diluted) | -18.62 | -71.75 | -62.93 | -91.41 | -167.54 | Upgrade
|
| Free Cash Flow | -28.98 | -72.35 | -64.35 | -43.55 | -29.21 | Upgrade
|
| Free Cash Flow Per Share | -18.65 | -55.56 | -64.60 | -72.02 | -112.45 | Upgrade
|
| Gross Margin | -152.76% | 11.34% | - | - | - | Upgrade
|
| Operating Margin | -7425.38% | -3959.13% | -4205.90% | -4034.48% | -15303.51% | Upgrade
|
| Profit Margin | -7266.08% | -6090.94% | -4023.11% | -4055.61% | -15267.72% | Upgrade
|
| Free Cash Flow Margin | -7280.15% | -4716.36% | -4130.36% | -3195.08% | -10247.37% | Upgrade
|
| EBITDA | -29.09 | -60.26 | -65.25 | -53.92 | -42.61 | Upgrade
|
| D&A For EBITDA | 0.46 | 0.47 | 0.28 | 1.07 | 1 | Upgrade
|
| EBIT | -29.55 | -60.73 | -65.53 | -54.99 | -43.62 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.